AstraZeneca shells out $4.1bn for diabetes business
Friday, December 20, 2013 - 10:40
in Psychology & Sociology
Bristol-Myers Squibb exits the diabetes field with plans to become a specialised biopharmaceutical company
Updated by artificial intelligence Tue, 13 Jun 2023, 2:53:47 UTC Learn more
- Tell your friends
- Get science news via